Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Macular Edema AND Retinopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Diabetes AND Macular Edema AND Retinopathy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2009-010536-17 Sponsor Protocol Number: C-09-003 Start Date*: 2009-08-31
    Sponsor Name:ALCON RESEARCH, LTD.
    Full Title: A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients
    Medical condition: macular edema following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051240 Cystoid macular edema LLT
    9.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FR (Completed) DE (Completed) ES (Prematurely Ended) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002089-74 Sponsor Protocol Number: Matyus-2008/1 Start Date*: 2008-08-15
    Sponsor Name:Semmelweis University
    Full Title: The investigation of the effect of dihydralazine (Depressan) on macular edema of type 2 diabetes patients and of inhibition of semicarbazide-sensitive amine oxidase (SSAO).
    Medical condition: Macular edema in patients with type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    9.1 10012675 Diabetic macular retinopathy LLT
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005400-14 Sponsor Protocol Number: WONR1001 Start Date*: 2008-07-25
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: PERIOPERATIVE INTRAVITREAL TRIAMCINOLONE IN PHAKOEMULSIFICATION FOR CONCURRENT CLINICALLY SIGNIFICANT DIABETIC MACULAR OEDEMA
    Medical condition: Diabetic Maculopathy: Clinically significant macular oedema To understand the effects of intravitreal triamcinolone (IVTA) in the treatment of clinically significant macular edema (CSME) in diabet...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003304-20 Sponsor Protocol Number: OKHN1006 Start Date*: 2012-07-02
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Randomised Controlled Trial of Intravitreal therapy with Avastin compared to Observation in Patients with Diabetic Ischaemic Macular Oedema ‘The DIME study’
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001553-26 Sponsor Protocol Number: Protocol 03_10_2007 Start Date*: 2008-03-13
    Sponsor Name:Vienna Medical University, Dept. of Ophthalmology
    Full Title: A randomized, double-masked study with intraocular bevacizumab (Avastin®) compared with intraocular triamcinolone (Volon A®) in patients with clinical significant diabetic macular edema
    Medical condition: Patients with persisting macular edema due to diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000031-27 Sponsor Protocol Number: Start Date*: 2013-03-20
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Intravitreal Ranibizumab (Lucentis) Therapy in Patients with Diabetic Ischaemic Macular Oedema (DIME)
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003147-27 Sponsor Protocol Number: B1261009 Start Date*: 2014-01-10
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY 10017 US
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF ...
    Medical condition: PF-04634817 is a small molecule chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy and diabetic macular edema.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    18.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000959-24 Sponsor Protocol Number: DMOE-001-10 Start Date*: 2015-08-10
    Sponsor Name:Abteilung für Augenheilkunde, AKH Linz
    Full Title: Clinical characterization of the treatment of diabetic macular edema with aflibercept in an outpatient setting by evaluation of a regional network of ophthalmologic care givers
    Medical condition: Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000900-15 Sponsor Protocol Number: B7A-MC-MBCU Start Date*: 2005-08-19
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography
    Medical condition: Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the m...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005315-10 Sponsor Protocol Number: 2006-011 Start Date*: 2006-09-05
    Sponsor Name:OSPEDALE SACRO CUORE-DON CALABRIA
    Full Title: Evaluation of safety and efficacy on visual acuity outcome of intravitreal somministration of Bevacizumab in patients with diabetic retinopathy
    Medical condition: Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001469-28 Sponsor Protocol Number: SA2008 Start Date*: 2009-06-17
    Sponsor Name:Dep. of Ophthalmology, Medical University of Vienna
    Full Title: A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with intravitreal Ranibizumab (Lucentis®) in patients with persistent diabetic macular edema or persistent active ...
    Medical condition: persistent diabetic macula edema or persistent diabetic proliferative retinopathy after lasercoagulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003165-13 Sponsor Protocol Number: 03 Start Date*: 2007-02-15
    Sponsor Name:Dep. Ophthalmology, Medical University of Vienna
    Full Title: A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema or persistent active neovascularisat...
    Medical condition: persistent diabetic macular edema or persistent active neovascularisation following lasercoagulation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001064-37 Sponsor Protocol Number: S348.2.001 Start Date*: 2008-07-31
    Sponsor Name:Fournier Laboratories Ireland
    Full Title: Effect of Choline Fenofibrate (ABT-335 /SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects with Diabetic Macular Edema - a one-year, Placebo-Controlled, Randomized Study
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) NL (Completed) GB (Completed) ES (Completed) HU (Completed) AT (Prematurely Ended) DK (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022364-12 Sponsor Protocol Number: BAY86-5321/91745 Start Date*: 2011-03-18
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema
    Medical condition: Diabetic macular edema with central involvement
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-004996-12 Sponsor Protocol Number: 206207-010 Start Date*: 2006-08-25
    Sponsor Name:Allergan Limited
    Full Title: A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Ap...
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) AT (Prematurely Ended) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000581-23 Sponsor Protocol Number: CSPP100A2244 Start Date*: 2008-07-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema
    Medical condition: Diabetic Macular Edema (DME) in hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004997-10 Sponsor Protocol Number: 206207-011 Start Date*: 2007-01-09
    Sponsor Name:Allergan Limited
    Full Title: A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Ap...
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000250-19 Sponsor Protocol Number: CADODIAME Start Date*: 2017-06-13
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR)
    Full Title: Effect of calcium dobesilate in early stages of diabetic retinopathy
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001213-36 Sponsor Protocol Number: ISTH-02-211 Start Date*: 2021-06-20
    Sponsor Name:Isarna Therapeutics GmbH
    Full Title: TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study
    Medical condition: Neovascular age-related macular degeneration (nAMD) Diabetic Macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000031-28 Sponsor Protocol Number: CLKA651X2202 Start Date*: 2019-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:22:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA